Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Treatment of Insomnia in Patients With HIV Disease

This study has been completed.
Information provided by (Responsible Party):
Duke University Identifier:
First received: April 25, 2007
Last updated: July 26, 2013
Last verified: May 2013
Results First Received: December 12, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: HIV Infections
Interventions: Drug: Doxepin
Drug: Temazepam
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited from an HIV clinic in the Department of Internal Medicine, Duke University Medical Center

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment

We initially planned to have 3 arms: placebo, temazepam, and doxepin. However, based on the rate of recruitment, we limited the study to 2 arms: placebo and temazepam.

Screening was carried out which included medical, and psychiatric, and sleep assessments.

Reporting Groups
Placebo One sugar pill taken orally at bedtime for duration of the participant's involvement.
Temazepam One 15 mg temazepam pill taken orally at bedtime for the duration of the participant's involvement.

Participant Flow:   Overall Study
    Placebo   Temazepam
STARTED   20   24 
COMPLETED   18   23 
Withdrawal by Subject                2                1 

  Baseline Characteristics

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Response: Change in Insomnia Severity Rating Scale at 3 Months.   [ Time Frame: Baseline and 3 months ]

2.  Secondary:   Change in Piper Fatigue Scale at 3 Months   [ Time Frame: Baseline and 3 months ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information